Full Summary
This Thursday morning, OpenAI CEO Sam Altman is in Washington, where both Reuters and The Tech Buzz confirm he is publicly backing President Trump's new executive order on artificial intelligence. This comes as Semafor reports AI companies are intensely lobbying Congress for federal AI regulation. Altman's visit to the White House and Capitol Hill comes as OpenAI prepares for a potential public offering, as noted by Claims Journal. However, The Hindu reports Altman will urge U.S. lawmakers *against* requiring government approval for new AI models, instead advocating for increased funding for AI testing at the Department of Commerce. Meanwhile, multiple sources, including Gizmodo, The Independent, and AOL.com, confirm a rare moment of unity among AI rivals: Sam Altman, along with Anthropic CEO Dario Amodei, Google DeepMind's Demis Hassabis, and Microsoft AI's Mustafa Suleyman, have signed an open letter. They are calling for new laws to prevent AI from being used to create bioweapons, specifically urging mandatory screening of synthetic nucleic acid purchases. Benzinga adds that nearly 75 leaders believe AI is lowering the "know-how barrier" for dangerous lab methods. In other news, Florida has filed a lawsuit against OpenAI and Sam Altman, with The Globe and Mail and Memeburn both reporting allegations that ChatGPT endangers children by aiding mass shooters and encouraging self-harm. OpenAI rejects claims of ignoring safety, citing parental controls. The AI industry itself is facing a cash crunch. CTech reports that tech giants alone are set to invest at least $700 billion in AI infrastructure this year, potentially topping $1 trillion industry-wide. This spending forces companies to find new ways to secure capital. Goldman Sachs CEO David Solomon, as reported by Moneywise.com and Yahoo Finance, believes investor "greed" and optimism will prevent an AI bubble from bursting, noting ample liquidity for upcoming IPOs from companies like Anthropic and OpenAI. This intense activity means the future of AI development and its regulation is being actively shaped right now, directly impacting the safety and cost of the AI tools you'll use in your daily life.